RHOPHYLAC Solution for injection Ref.[6195] Active ingredients: Anti-D (rh) immunoglobulin

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2019  Publisher: CSL Behring GmbH, Emil-von-Behring-Strasse 76, 35041, Marburg, Germany

Product name and form

Rhophylac 300 micrograms/2 ml, solution for injection in pre-filled syringe.

Pharmaceutical Form

Solution for injection.

The solution is clear or slightly opalescent and colourless or pale yellow.

Rhophylac has an osmolality of at least 240 mosmol/kg.

Qualitative and quantitative composition

Each pre-filled syringe contains 300 micrograms (1500 IU) human anti-D immunoglobulin*.

One ml contains 150 micrograms (750 IU) human anti-D immunoglobulin.

The product contains a maximum of 30 mg/ml of human plasma proteins of which 10 mg/ml is human albumin as stabiliser. At least 95% of the other plasma proteins are IgG.

Distribution of the IgG subclasses (approximate values):

IgG1: 84.1%
IgG2: 7.6%
IgG3: 8.1%
IgG4: 1.0%

The content of immunoglobin A (IgA) is not more than 5 micrograms/ml.

* Produced from the plasma of human donors.

Excipient with known effect:

This medicine contains less than 1 mmol sodium (23 mg) per syringe, that is to say essentially “sodium-free”.

Rhophylac contains no preservatives.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Anti-D (rh) immunoglobulin

Human anti-D immunoglobulin contains specific antibodies (IgG) against the Rh(D) antigen of human erythrocytes. It can also contain antibodies to other Rh antigens, e.g. anti-Rh C antibodies. The mechanism by which anti-D immunoglobulin suppresses immunisation to Rh(D) positive red cells is not known.

List of Excipients

Human albumin
Glycine
Sodium chloride
Water for injections

Pack sizes and marketing

2 ml solution in a pre-filled syringe (type I glass) with 1 injection needle in a pack size of 1 or in a multi-pack consisting of 5 single packs.

Not all pack sizes may be marketed.

Marketing authorization holder

CSL Behring GmbH, Emil-von-Behring-Strasse 76, 35041, Marburg, Germany

Marketing authorization dates and numbers

PL 15036/0019

01 June 2006

Drugs

Drug Countries
RHOPHYLAC Austria, Brazil, Cyprus, Ecuador, Spain, Finland, France, Ireland, Malta, Netherlands, Poland, Romania, Tunisia, Turkey, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.